PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTreosulfan
Treosulfan
Trecondi (treosulfan) is a small molecule pharmaceutical. Treosulfan was first approved as Trecondi on 2019-06-20. It has been approved in Europe to treat hematopoietic stem cell transplantation.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
therapeuticsD013812
operative surgical proceduresD013514
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AB: Alkyl sulfonate alkylating agents
— L01AB02: Treosulfan
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9531541—20
Precursor cell lymphoblastic leukemia-lymphomaD054198——1741—11
Lymphoid leukemiaD007945—C91—331—6
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D463141——16
Myeloid leukemia acuteD015470—C92.02113——15
MelanomaD008545———11——2
SarcomaD012509————1——1
Ewing sarcomaD012512EFO_0000173———1——1
Ovarian neoplasmsD010051EFO_0003893C56——1——1
Ovarian epithelial carcinomaD000077216————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PreleukemiaD011289——211———12
SyndromeD013577——110———10
Hematologic neoplasmsD019337——27———8
Myeloid leukemiaD007951—C92—8———8
Myelomonocytic leukemia juvenileD054429—C93.315———5
Multiple myelomaD009101—C90.024———5
NeoplasmsD009369—C8024———5
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340——4———4
Myelomonocytic leukemia chronicD015477—C93.114———4
LymphomaD008223—C85.9—3———3
Show 45 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematopoietic stem cell transplantationD018380——1———12
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTreosulfan
INNtreosulfan
Description
Treosulfan is a methanesulfonate ester.
Classification
Small molecule
Drug classantineoplastics, alkylating agents (methane sulfonate derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
Identifiers
PDB—
CAS-ID299-75-2
RxCUI—
ChEMBL IDCHEMBL455186
ChEBI ID82557
PubChem CID9882105
DrugBankDB11678
UNII IDCO61ER3EPI (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,636 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,977 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use